News Items
The prospects of success-fully developing a coron-avirus vaccine as soon as this year were buoyed Monday when three of the world’s leading candi-dates reported positive early trial data.
++++++
Led by epicenters in Brazil, India and the U.S., skyrocketing cases around the world are nearing 15 million, even as new developments in the search for a potential vaccine are stoking optimism. On Monday, AstraZeneca (AZN) said its experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials.
#####
Inovio Pharmaceuticals has reported positive interim results from the initial two cohorts in Phase I clinical trial of its Covid-19 vaccine candidate, INO-4800.
######
In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.